New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 5
Revenue ttm 0
Net income ttm (193)
Free cash flow ttm (15)
Net debt Q (180)
Valuation
P/E n/m
Forward P/E FY16e —
Price / sales 37.9 (above 10: high)
Forward P/S FY16e Powerpack
Price / FCF n/m
Price / book n/m
Financial health
Current ratio Q 97.7 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (25.3)
Growth
Revenue growth FY16e —
EPS growth FY16e +89.4% (at or above 15%: strong)
EPS growth FY17e +41.5% (at or above 15%: strong)
EPS growth, 5 yrs e +62.1% (at or above 15%: strong)
Insiders
Net bought 12m 0
Sells 12m 0
Buys 12m 42
Owned by insiders 20.0%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY16e the fiscal year ending in 2016; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (24.64%) (9.28%)

Valuation

P/S against its own 10 years 25.69%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — 0 — 40 — — —
Gross margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — — 0.00 0.0 pt
EBT (2) (2) (5) (4) (15) (12) (27) (11) (12) (14) (193) +24.3%
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
Net income (2) (2) (4) (3) (14) (11) (27) (11) (12) (14) (193) +24.3%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings (228.93) (210.08) (350.14) (350.00) (960.92) (375.00) (850.00) (212.00) (96.75) (10.36) (58.78) (29.1%)
Cash flow (256.55) (177.91) (346.53) (247.76) (209.55) (284.88) (298.29) (153.59) (91.87) (8.70) (4.59) (31.3%)
Capex (2.83) (2.22) (2.08) 0.00 0.00 0.00 0.00 (0.05) (0.03) (0.65) (0.39) (15.1%)
Free cash flow (259.38) (180.13) (348.62) (247.76) (209.55) (284.88) (298.29) (153.64) (91.90) (9.35) (4.99) (30.9%)
Book value 269.90 40.13 906.64 721.86 1,529.30 832.85 232.01 95.03 13.86 4.26 (60.99) (36.9%)
Shares, m 0 0 0 0 0 0 0 0 0 1 2 +75.2%
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow (2) (2) (4) (3) (3) (9) (10) (8) (11) (11) (14) +20.3%
Capex 0 0 0 — — — — 0 0 (1) (1) +48.8%
Free cash flow (2) (2) (4) (3) (3) (9) (10) (8) (11) (12) (15) +21.1%
Balance, $m
Balance, $m Working capital 2 0 1 0 15 17 7 5 0 3 180 +4.9%
Net debt (2) 0 (2) 0 (15) (16) (7) (5) (1) (6) (180) +11.4%
Shareholders’ equity 2 0 10 8 23 25 7 5 2 6 (181) +10.5%
Returns, %
Returns, % ROA (155.28) (69.42) (48.69) (33.08) (79.86) (44.23) (156.34) (154.40) (262.87) (245.66) (203.76) (90.4) pt
ROIC (682.35) 0.00 (34.53) (29.74) (125.00) (84.38) (1,309.15) (2,530.28) (1,491.78) (21,694.32) 0.00 (21,012.0) pt
ROE (1,329.47) (140.61) (74.75) (43.64) (93.14) (47.20) (166.43) (178.52) (354.51) (372.96) 220.06 +956.5 pt
People
People Employees 1 13 15 13 14 15 15 13 10 12 — +31.8%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2015 · latest quarter Mar 2016 · fundamentals updated 18 Nov 2026

Heatwurx Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RVPH Reviva Pharmaceuticals Holdings, Inc. $5.0M — (loss-making) — — n/m +60.92% (above 0%: growing) — 0.00% Compare
NIKI Niki BioSolutions, Inc. $5.0M — (loss-making) 31.9× FY24e −32.36% (below 0%: shrinking) — +58.14% (above 0%: growing) (154.22%) 0.00% Compare
LTRN Lantern Pharma Inc. $4.9M — (loss-making) — — n/m +25.31% (above 0%: growing) 0.00% 0.00% Compare
PULM Pulmatrix, Inc. $4.9M — (loss-making) — (loss-making) −99.86% (below 0%: shrinking) n/m +25.32% (above 0%: growing) 100.00% 0.00% Compare
CDIO Cardio Diagnostics Holdings, Inc. $4.9M — (loss-making) — (loss-making) +24.14% (above 0%: growing) n/m +2.59% (above 0%: growing) 100.00% (48,061.11%) Compare
PCSA Heatwurx Inc. $4.8M — (loss-making) — −64.29% (below 0%: shrinking) n/m −48.55% (below 0%: shrinking) 0.00% 0.00%
JAGX Jaguar Animal Health, Inc. $4.7M 0.0× — (loss-making) −24.00% (below 0%: shrinking) n/m −3.92% (below 0%: shrinking) 73.24% (257.06%) Compare
CANF Can-Fite Biopharma Ltd $4.6M — (loss-making) — (loss-making) −1.18% (below 0%: shrinking) n/m +12.63% (above 0%: growing) 0.00% 0.00% Compare
SKYE Skye Bioscience, Inc. $4.6M — (loss-making) — −34.71% (below 0%: shrinking) n/m +61.34% (above 0%: growing) 72.71% 0.00% Compare
Median of peers $4.9M — — −28.18% — +25.32% 72.71% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 673.30k 565.07k 2.00
2024 521.03k 288.39k 13.00
2023 472.85k 428.85k 100.00

Ownership

Directors and executive officers, together 12.30%
The Chiliz Group 10.90%
Entities affiliated with CVI Investments, Inc. 6.70%
Entities affiliated with Soleus Capital 5.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Heatwurx Inc. (PCSA) Latest News

20 more headlines
All PCSA news, as stories →
stockrow.com/PCSA · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com